Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Abbott to pay US$385 million in US settlement over contaminated infant formula allegations

Unsanitary conditions at firm’s Michigan plant include roof leaks and inadequate cleaning procedures

Leading infant formula company Abbott will pay nearly US$385 million to settle allegations that its Sturgis, Michigan plant manufactured products that did not meet safety standards. The US Justice Department announced the settlement on Monday (Sep 14), following years of scrutiny of the facility, which produces a significant portion of the US' formula supply.

In 2022, Abbott initiated a recall of powdered formulas produced at the plant after federal health officials linked the products to four infants hospitalised with rare bacterial infections, two of whom died. The recall led to a nationwide shortage of infant formula for months.

Abbott did not admit liability or fault in the settlement, stating that "no unopened, distributed Abbott infant formulas have ever tested positive" for the bacteria that sickened the babies. The federal government's complaint alleged unsanitary conditions at the Michigan plant, including roof leaks, deteriorating equipment, and inadequate cleaning procedures.

Instead of fixing the roof leaks, Abbott installed umbrellas, creating a wet environment that fostered bacterial growth. The plant's spray dryers, used to convert liquid formula into powder, had cracks and pits that increased the risk of contamination. Abbott also allegedly chose not to test for bacterial contamination and withheld positive test results from the US Food and Drug Administration.

The settlement will distribute funds to the federal government, state Medicaid, and the federal nutrition programme for women, infants, and children. Three whistleblowers who first reported the plant's issues will receive US$69 million. Abbott has a history of prioritising safety and compliance in its plants, according to a 2022 statement.

Written by urgent.news from The Business Times - Companies & Markets's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at businesstimes.com.sg →

More in Health & Medicine

Celltrion Moves to Expand Zymfentra Use in the U.S. With New Phase 4 Trial

Celltrion is accelerating clinical development of Zymfentra in the United States as it seeks to expand the drug’s prescribing options beyond its current 120mg dose.The South Korean biopharmaceutical…

  • Celltrion initiates Phase 4 trial for Zymfentra in U.S., testing 240mg dose.
  • 447 patients with Crohn's disease or ulcerative colitis to participate across 55 centers.
  • Successful trial could provide U.S. doctors two-dose treatment option for autoimmune diseases.

FCT inaugurates task force to reduce maternal deaths

The Federal Capital Territory (FCT) Administration has inaugurated a task force under the Maternal Mortality Reduction Innovation Initiative (MAMII) to coordinate efforts aimed at reducing maternal…

  • FCT inaugurates task force under Maternal Mortality Reduction Initiative
  • Task force to address maternal and newborn deaths in territory
  • Initiative supports interventions for pregnant women and healthcare facilities

More from Tuesday 15 September →